Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study

乌斯特基努马 医学 银屑病 观察研究 肺结核 潜伏性肺结核 回顾性队列研究 慢性肝炎 斑块性银屑病 结核分枝杆菌 内科学 病毒学 免疫学 病毒 疾病 病理 阿达木单抗
作者
Wensheng Lü,Jianfeng Wang,Yuanjing Zhang,Ruixue Chang,Jun Zhao
出处
期刊:Clinical, Cosmetic and Investigational Dermatology [Dove Medical Press]
卷期号:Volume 17: 1413-1422 被引量:3
标识
DOI:10.2147/ccid.s454971
摘要

Introduction: This study observed the effectiveness of ustekinumab and reactivation risk of concurrent latent tuberculosis infection (LTBI) and inactive hepatitis B virus (HBV) infection in Chinese mainland psoriasis patients on ustekinumab treatment. Methods: This retrospective, multicenter, observational study was conducted in three centers in China. Adult patients with moderate to severe plaque psoriasis were treated with ustekinumab for 28 weeks. The effectiveness endpoint included 75% and 90% improvement in Psoriasis Area Severity Index (PASI75/90) response rate, percentage of PASI improvement, change of absolute PASI score and body surface area involvement (BSA) score, absolute PASI ≤1/3 and Physicians' Global Assessment (PGA)=0/1, as well as Dermatology life quality index (DLQI)=0/1 response rate at week 4, 16 and 28. Screening of tuberculosis and hepatitis were performed at baseline and week 28. Results: A total of 82 patients were enrolled between March 2021 and May 2023 and the number of patients combined with LTBI and inactive HBV infection was 20 and 21 respectively. The PASI75 and PASI90 response rate at week 28 was 95.1% and 81.7% respectively. The mean PASI score decreased from 14.93 ± 12.07 at baseline to 0.78 ± 1.86 at week 28, and the mean BSA score decreased from 21% ± 18% at baseline to 1% ± 2% at week 28 (both P<0.001 compared with baseline). DLQI 0/1 response rate at week 28 was 73.2%. No reactivation of LTBI and inactive HBV infection and also no new-onset tuberculosis and hepatitis B occurred in patients without LTBI and inactive HBV infection at baseline. Conclusion: Ustekinumab demonstrated great effectiveness in Chinese plaque psoriasis patients and good safety in psoriasis concurrent with LTBI and inactive HBV infection under the real-world setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顺利追命完成签到 ,获得积分10
1秒前
Citrofrost完成签到,获得积分10
1秒前
2秒前
领导范儿的应助被袋袋采纳,获得10
2秒前
叫滚滚发布了新的文献求助10
3秒前
4秒前
4秒前
yebo发布了新的文献求助10
4秒前
lmy发布了新的文献求助10
4秒前
4秒前
5秒前
whatever的应助被女巫在跳舞采纳,获得50
6秒前
7秒前
小亮完成签到 ,获得积分10
8秒前
lingo发布了新的文献求助20
9秒前
chen完成签到,获得积分20
10秒前
胡佳琦发布了新的文献求助10
10秒前
科研通AI6.4的应助被孙家贝采纳,获得10
10秒前
11秒前
1461644768完成签到,获得积分10
11秒前
风吹麦浪发布了新的文献求助10
11秒前
在水一方的应助被zzk采纳,获得10
11秒前
领导范儿的应助被loren采纳,获得20
11秒前
11秒前
12秒前
科研完成签到,获得积分10
12秒前
12秒前
12秒前
13秒前
13秒前
14秒前
fx发布了新的文献求助10
14秒前
15秒前
he发布了新的文献求助10
15秒前
科研通AI6.4的应助被简单生活采纳,获得10
15秒前
16秒前
杜梦婷发布了新的文献求助10
16秒前
qinglan完成签到,获得积分10
16秒前
zhang5657完成签到,获得积分10
16秒前
sl发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239